Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010

J Manag Care Pharm. 2010 Oct;16(8):629-39. doi: 10.18553/jmcp.2010.16.8.629.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Bevacizumab
  • Breast Neoplasms / drug therapy
  • Dibenzothiazepines / adverse effects
  • Dibenzothiazepines / therapeutic use
  • Drug Costs
  • Drug Labeling
  • Health Services Accessibility
  • Insurance, Health, Reimbursement
  • Legislation, Drug / trends*
  • Midodrine / adverse effects
  • Midodrine / therapeutic use
  • Off-Label Use / legislation & jurisprudence*
  • Prescription Drugs* / economics
  • Quetiapine Fumarate
  • United States
  • Vasoconstrictor Agents / adverse effects
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Prescription Drugs
  • Vasoconstrictor Agents
  • Quetiapine Fumarate
  • Bevacizumab
  • Midodrine